JP2015180198A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015180198A5 JP2015180198A5 JP2015044097A JP2015044097A JP2015180198A5 JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5 JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015044097 A JP2015044097 A JP 2015044097A JP 2015180198 A5 JP2015180198 A5 JP 2015180198A5
- Authority
- JP
- Japan
- Prior art keywords
- serine
- serine racemase
- barrier function
- expression level
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019820 SRR Human genes 0.000 claims 15
- 108010006152 serine racemase Proteins 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 9
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 6
- 230000004625 regulation of water loss via skin Effects 0.000 claims 6
- 210000002510 Keratinocytes Anatomy 0.000 claims 5
- 210000003491 Skin Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 3
- 150000008574 D-amino acids Chemical class 0.000 claims 2
- 241000283074 Equus asinus Species 0.000 claims 2
- 108020004999 Messenger RNA Proteins 0.000 claims 2
- 229960001327 Pyridoxal Phosphate Drugs 0.000 claims 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims 2
- 230000004888 barrier function Effects 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 229920002106 messenger RNA Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims 2
- 239000000758 substrate Substances 0.000 claims 2
- -1 vitamin B 6 compound Chemical class 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Claims (12)
ケラチノサイトに、候補薬剤を添加する工程、
ケラチノサイトにおいてセリンラセマーゼの活性若しくは発現量、及び/又はＤ−セリン量を測定する工程、
セリンラセマーゼ発現量若しくは活性、及び/又はＤ−セリン量から、候補薬剤の皮膚のバリア機能亢進作用を決定する工程
を含む、請求項１に記載のスクリーニング方法。 below:
Adding a candidate drug to keratinocytes;
A step of measuring the activity or expression level of serine racemase and / or the amount of D-serine in keratinocytes,
The screening method of Claim 1 including the process of determining the barrier function enhancement effect | action of the skin of a candidate chemical | medical agent from serine racemase expression level or activity, and / or D-serine amount.
対象から単離された皮膚サンプルにおいて、セリンラセマーゼ活性若しくは発現量及び／又はＤ−セリン量を測定する工程、
セリンラセマーゼ活性若しくは発現量及び／又はＤ−セリン量から、対象の皮膚のバリア機能を決定する工程
を含む、請求項８に記載の皮膚バリア機能を評価する方法。 below:
Measuring a serine racemase activity or expression level and / or D-serine level in a skin sample isolated from a subject,
The method for evaluating the skin barrier function according to claim 8, comprising a step of determining the barrier function of the subject's skin from the serine racemase activity or expression level and / or the D-serine level.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015044097A JP6854073B2 (en) | 2014-03-05 | 2015-03-05 | Screening method for skin barrier function enhancing drug and skin barrier function evaluation method using the amount of epidermal serine racemase and / or D-serine as an index |
| JP2019186327A JP6934925B2 (en) | 2014-03-05 | 2019-10-09 | Serine racemase activator and skin barrier enhancer |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014043073 | 2014-03-05 | ||
| JP2014043073 | 2014-03-05 | ||
| JP2015044097A JP6854073B2 (en) | 2014-03-05 | 2015-03-05 | Screening method for skin barrier function enhancing drug and skin barrier function evaluation method using the amount of epidermal serine racemase and / or D-serine as an index |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Division JP6934925B2 (en) | 2014-03-05 | 2019-10-09 | Serine racemase activator and skin barrier enhancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015180198A JP2015180198A (en) | 2015-10-15 |
| JP2015180198A5 true JP2015180198A5 (en) | 2016-04-28 |
| JP6854073B2 JP6854073B2 (en) | 2021-04-07 |
Family
ID=54328827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015044097A Active JP6854073B2 (en) | 2014-03-05 | 2015-03-05 | Screening method for skin barrier function enhancing drug and skin barrier function evaluation method using the amount of epidermal serine racemase and / or D-serine as an index |
| JP2019186327A Active JP6934925B2 (en) | 2014-03-05 | 2019-10-09 | Serine racemase activator and skin barrier enhancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019186327A Active JP6934925B2 (en) | 2014-03-05 | 2019-10-09 | Serine racemase activator and skin barrier enhancer |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP6854073B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018174286A1 (en) * | 2017-03-24 | 2018-09-27 | 味の素株式会社 | Stratum corneum function improving agent |
| JP7366428B2 (en) * | 2018-08-27 | 2023-10-23 | Kagami株式会社 | Skin sample analysis method and system for determining psoriasis |
| JP7237689B2 (en) * | 2019-03-28 | 2023-03-13 | 株式会社ナリス化粧品 | Screening method for agent for improving skin barrier function caused by stress |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120148509A1 (en) * | 2009-09-14 | 2012-06-14 | Shiseido Company, Ltd. | Composition for alleviating ultraviolet irradiation-induced damage |
-
2015
- 2015-03-05 JP JP2015044097A patent/JP6854073B2/en active Active
-
2019
- 2019-10-09 JP JP2019186327A patent/JP6934925B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsang et al. | Purpurin suppresses Candida albicans biofilm formation and hyphal development | |
| BR112017010190A2 (en) | feature measurement system, measurement method | |
| Cappellari et al. | “The Social Network” and muscular dystrophies: the lesson learnt about the niche environment as a target for therapeutic strategies | |
| MX2018004067A (en) | Quencher containing water soluble polymer-conjugated nanomaterial and use thereof. | |
| MX2015014892A (en) | Method for a cell-based drug screening assay and the use thereof. | |
| JP2015180198A5 (en) | ||
| Mindaye et al. | Impact of influenza A virus infection on the proteomes of human bronchoepithelial cells from different donors | |
| JP2015511721A5 (en) | ||
| RU2017122187A (en) | CELLULAR METHOD FOR DETERMINING DEFIBROTIDE EFFICIENCY | |
| JP2004527244A5 (en) | ||
| AU2018275891A1 (en) | Articles of manufacture and methods related to toxicity associated with cell therapy | |
| MY196578A (en) | Method for Determining Stage of Periodontal Disease | |
| DE602005008710D1 (en) | METHOD FOR EXAMINING THE ACTIVITY OF ION CHANNELS | |
| RU2012153849A (en) | METHOD FOR ESTIMATING TOXICITY OF PRODUCTS FROM POLYMERIC AND TEXTILE MATERIALS | |
| Ilić et al. | Syphacia obvelata modifies mitogen-activated protein kinases and nitric oxide synthases expression in murine bone marrow cells | |
| Gordhan et al. | Ex vivo challenge models for infectious diseases | |
| Samarelli et al. | Small molecules for the treatment of long-COVID-related vascular damage and abnormal blood clotting: a patent-based appraisal | |
| RU2017139718A (en) | AGENT, INDUCING CELLULAR DESTRUCTION, FOR CELLS, which is equipped with a drawing-up of text-taking graphics (APIs), EPS AGENT, GROWTH FOR THOSE CELLS, and PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES, IT-ALUMNI; | |
| AR102509A1 (en) | TEST KIT TO DETERMINE THE ACTIVITY OF A SOLUTION CONTAINING CUAT | |
| JP2014028787A5 (en) | ||
| Hagihara et al. | An experimental study about survey response rate Basic study of efficient strategies to raise the participation rate of Mobility Management | |
| Chastel | Emergence of new viruses in Asia: is climate change involved? | |
| RU2015120411A (en) | Method for assessing periodontal colonization by pathogenic bacteria using real-time polymerase chain reaction | |
| JP2013242298A5 (en) | ||
| Melnikov et al. | Integral approach to evaluation of the pathogenic activity of Trypanosoma cruzi clones as exemplified by the Mexican strain |